News | December 15, 2010

New Publication Highlights Anticoagulant Therapy

December 15, 2010 – A guest editorial in the new publication Clinical Investigation highlights dabigatran etexilate as an alternative to warfarin for long-term stroke prevention in patients with non-valvular atrial fibrillation.

In the article, Jeffrey Weitz, M.D., and John Eikelboom, both from McMaster University in Hamilton, Canada, discuss the importance of the U.S. Food and Drug Administration’s (FDA) approval of dabigatran etexilate (Pradaxa) in October. Pradaxa is made by Boehringer Ingelheim.

Non-valvular atrial fibrillation is a heart rhythm abnormality that is an important risk factor for stroke. Prophylactic anticoagulation with warfarin is commonly used, but it is a notoriously difficult drug to administer. The appropriate dose varies from patient to patient, and is based on the patient’s genetic profile, differences in the dietary intake of vitamin K and multiple drug interactions. Response to warfarin is so variable that frequent monitoring is necessary to ensure that the level of anticoagulation is therapeutic.

Such monitoring is burdensome for patients and physicians alike, and costly for the healthcare system. Even when monitoring is performed, the level of anticoagulation is above or below the therapeutic range in at least half the patients, with consequent risk of bleeding or thrombosis. As a result, warfarin tends to be underused for stroke prevention in patients with atrial fibrillation.

Dabigatran etexilate is an oral anticoagulant that can be given in a fixed dose and results in such a predictable level of anticoagulation that monitoring is unnecessary.

The advantages over warfarin include a rapid onset of action, predictable anticoagulant effect and low potential for interactions with food or other drugs. It does require twice daily administration, and methods to monitor its anticoagulation effect are not yet well developed. The drug is also not suitable for those with severe renal impairment, and because there is no antidote, there is an increased risk of bleeding in patients requiring urgent procedures. Nevertheless, the authors summarize, “The approval of dabigatran etexilate as an alternative to warfarin for stroke prevention in atrial fibrillation ushers in a new era for long-term anticoagulation.”

Several other new oral anticoagulants are also in advanced stages of development. These agents, including rivaroxaban, apixaban and edoxaban, are oral factor Xa inhibitors and share many of the advantages of dabigatran etexilate over warfarin, and may have advantages over dabigatran itself.

For more information: www.future-science.com

Related Content

Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Overlay Init